GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » PE Ratio (TTM)

ZIVO (Zivo Bioscience) PE Ratio (TTM) : At Loss (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-13), Zivo Bioscience's share price is $18.10. Zivo Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.88. Therefore, Zivo Bioscience's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Zivo Bioscience's PE Ratio (TTM) or its related term are showing as below:

ZIVO' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



ZIVO's PE Ratio (TTM) is ranked worse than
100% of 246 companies
in the Biotechnology industry
Industry Median: 27.115 vs ZIVO: At Loss

Zivo Bioscience's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.67. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.88.

As of today (2024-12-13), Zivo Bioscience's share price is $18.10. Zivo Bioscience's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.88. Therefore, Zivo Bioscience's PE Ratio without NRI for today is At Loss.

Zivo Bioscience's EPS without NRI for the three months ended in Sep. 2024 was $-0.67. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.88.

During the past 3 years, the average EPS without NRI Growth Rate was 24.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 35.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 12.10% per year.

During the past 13 years, Zivo Bioscience's highest 3-Year average EPS without NRI Growth Rate was 54.60% per year. The lowest was -371.50% per year. And the median was 12.60% per year.

Zivo Bioscience's EPS (Basic) for the three months ended in Sep. 2024 was $-0.67. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.88.


Zivo Bioscience PE Ratio (TTM) Historical Data

The historical data trend for Zivo Bioscience's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zivo Bioscience PE Ratio (TTM) Chart

Zivo Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Zivo Bioscience Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Zivo Bioscience's PE Ratio (TTM)

For the Biotechnology subindustry, Zivo Bioscience's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zivo Bioscience's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zivo Bioscience's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Zivo Bioscience's PE Ratio (TTM) falls into.



Zivo Bioscience PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Zivo Bioscience's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=18.10/-4.880
=At Loss

Zivo Bioscience's Share Price of today is $18.10.
Zivo Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.88.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Zivo Bioscience  (OTCPK:ZIVO) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Zivo Bioscience PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zivo Bioscience Business Description

Traded in Other Exchanges
N/A
Address
21 East Long Lake Road, Suite 100, Bloomfield Hills, MI, USA, 48304
Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Companion Animal Food Ingredient, NDI (New Dietary Ingredient, and Skin Health.
Executives
John Bernard Payne director 9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Alison A Cornell director 210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore officer: CHIEF FINANCIAL OFFICER 4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson director 768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
Strome Mezzanine Fund, Lp 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando officer: Chief Financial Officer C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Strome Alpha Fund L P 10 percent owner 100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp 10 percent owner 100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc. 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc 10 percent owner 2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr director 70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox director 470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl officer: President, CEO 7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young other: See remarks below. 1800 NW CORPORATE BLVD, BOCA RATON FL 33431